Somatrogon
Red
Brand:
Ngenla
Nice TA:
863
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Endocrine system
Background
1.1 Somatrogon is recommended, within its marketing authorisation, as an option for treating growth disturbance caused by growth hormone deficiency in children and young people aged 3 years and over.
1.2 If people with the condition and their clinicians consider somatrogon to be 1 of a range of suitable treatments (including any preparation of somatropin) discuss the advantages and disadvantages of the available treatments. After that discussion, if more than 1 treatment is suitable, choose the least expensive. Take account of administration costs, dosage, price per dose and commercial arrangements.
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine
Supporting documents: